AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1699400 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 1699400 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 0
Study 1699400 — intervention group
Group type: COMPARATOR
Intervention: Class I antiarrhythmic agents (flecainide and encainide)
Number of subjects: 0
Study 1699400 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic agents (amiodarone)
Number of subjects: 0
Study 342629 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus vaccine (50 CCA units)
Number of subjects: 100
Study 342629 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus vaccine (two inoculations)
Number of subjects: 100
Study 342629 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-product vaccine
Number of subjects: 100
Study 342629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31856081 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 417
Study 31856081 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 417
Study 30952216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 139
Study 30952216 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (CTRL)
Number of subjects: 139
Study 28198465 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 28198465 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine-dopamine reuptake inhibitor (bupropion)
Number of subjects: 12
Study 28198465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25957981 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-PRP
Number of subjects: 58
Study 25957981 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study 23124786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetholone
Number of subjects: 43
Study 23124786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 21802026 — intervention group
Group type: EXPERIMENTAL
Intervention: ICX72 (Capsaicin nasal spray)
Number of subjects: 42
Study 21802026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18708287 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day arginine (ARG trial)
Number of subjects: 10
Study 18708287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON trial)
Number of subjects: 10
Study 22892773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml saline solution of Propionium bacterium parvum, one dose a month for 3 to 5 months
Number of subjects: 20
Study 22892773 — intervention group
Group type: COMPARATOR
Intervention: 0.1 ml intradermal injection of placebo solution
Number of subjects: 20
Study 15913168 — intervention group
Group type: EXPERIMENTAL
Intervention: External suction drainage (ESD) system
Number of subjects: 42
Study 15913168 — intervention group
Group type: COMPARATOR
Intervention: Conventional internal suction drainage (ISD) system
Number of subjects: 42
Study 12902415 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐Sestamibi scintigraphy
Number of subjects: 72
Study 12902415 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐Sestamibi scintigraphy in ERT-naive patients
Number of subjects: 72
Study 12902415 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐Sestamibi scintigraphy in ERT-treated patients
Number of subjects: 72
Study 9579503 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 351
Study 9579503 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter electrocardiography (ECG)
Number of subjects: 351
Study 9579503 — intervention group
Group type: COMPARATOR
Intervention: Both TEE and ECG
Number of subjects: 351
Study 9579503 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE
Number of subjects: 351
Study 9579503 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 351
Study 8617535 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and awareness of immunization among health personnel
Number of subjects: 634
Study 8617535 — intervention group
Group type: EXPERIMENTAL
Intervention: Attaching immunization slip to the outpatient form
Number of subjects: 634
Study 8617535 — intervention group
Group type: COMPARATOR
Intervention: Baseline survey (Phase-I)
Number of subjects: 634
Study 8617535 — intervention group
Group type: COMPARATOR
Intervention: Phase-II and Phase-III surveys after interventions
Number of subjects: 634
Study 2644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylose starch
Number of subjects: 12
Study 2644803 — intervention group
Group type: COMPARATOR
Intervention: Amylopectin starch
Number of subjects: 12
Study 556821 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 12
Study 556821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30431535 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 28
Study 30431535 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 28804801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation diet (PES‐d)
Number of subjects: 43
Study 28804801 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (Normal‐d)
Number of subjects: 43
Study 27117753 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 μg/kg in saline solution)
Number of subjects: 135
Study 27117753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 135
Study 26586385 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic E. coli Nissle 1917 for 6 weeks
Number of subjects: 139
Study 26586385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 23636302 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg, n=42)
Number of subjects: 132
Study 23636302 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg, n=24)
Number of subjects: 132
Study 23636302 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (n=66)
Number of subjects: 132
Study 20113522 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention with parents as the primary target group, engaging them in developing and implementing project ideas to promote physical activity.
Number of subjects: 37
Study 20113522 — intervention group
Group type: COMPARATOR
Intervention: State-sponsored programme providing structured gym lessons to preschool children (control group).
Number of subjects: 37
Study 20113522 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention with parents as the primary target group.
Number of subjects: 37
Study 18096304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of Sonazoid (0.6 microL microbubbles/kg body weight)
Number of subjects: 32
Study 18096304 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of Sonazoid (1.2 microL microbubbles/kg body weight over 30 min)
Number of subjects: 32
Study 18096304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bolus injection and continuous infusion of Sonazoid
Number of subjects: 32
Study 15899104 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 147
Study 15899104 — intervention group
Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 147
Study 12816354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E: 1.5 mL/kg, 370 mgI/mL, 5 mL/sec
Number of subjects: 125
Study 12816354 — intervention group
Group type: COMPARATOR
Intervention: Group A: 100 ml, 300 mgI/mL, 3 mL/sec
Number of subjects: 125
Study 12816354 — intervention group
Group type: COMPARATOR
Intervention: Group B: 2 mL/kg, 300 mgI/mL, 3 mL/sec
Number of subjects: 125
Study 12816354 — intervention group
Group type: COMPARATOR
Intervention: Group C: 1.5 mL/kg, 370 mgI/mL, 3 mL/sec
Number of subjects: 125
Study 12816354 — intervention group
Group type: COMPARATOR
Intervention: Group D: 2 mL/kg, 300 mgI/mL, 5 mL/sec
Number of subjects: 125
Study 10498008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained convergence for 30 seconds
Number of subjects: 0
Study 10498008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained convergence for 60 seconds
Number of subjects: 0
Study 10498008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained convergence for 90 seconds
Number of subjects: 0
Study 10498008 — intervention group
Group type: COMPARATOR
Intervention: Control duration of 5 seconds
Number of subjects: 0
Study 7847251 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective carboplatin (200 mg/m2 and 300 mg/m2) with concurrent infusional 5-fluorouracil (225 mg/m2) and radiotherapy
Number of subjects: 19
Study 7847251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusional 5-fluorouracil
Number of subjects: 19
Study 7847251 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective carboplatin delivery
Number of subjects: 19
Study 1719112 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study 1719112 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 0
Study 1719112 — intervention group
Group type: COMPARATOR
Intervention: Soft tissue manipulation
Number of subjects: 0
Study 1719112 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (SP) preincubation (1 x 10(‐11) M, 5 x 10(‐11) M, 1 x 10(‐10) M)
Number of subjects: 0
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise at 88 W
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise at 118 W
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation reducing Hb by 18.6%
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise Q 6 days post-blood donation
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise Q 11 days post-blood donation
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise Q 16 days post-blood donation
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximum exercise Q 21 days post-blood donation
Number of subjects: 28
Study 7333744 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of stroke volume (SV) post-blood donation
Number of subjects: 28
Study 30968444 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U C1‐INH, twice weekly for 12 weeks
Number of subjects: 12
Study 30968444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U C1‐INH, twice weekly for 12 weeks
Number of subjects: 12
Study 30968444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of C1‐INH
Number of subjects: 12
Study 30968444 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U C1‐INH
Number of subjects: 12
Study 30968444 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U C1‐INH
Number of subjects: 12
Study 30968444 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH prophylaxis
Number of subjects: 12
Study 27460979 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% glucose (G25)
Number of subjects: 78
Study 27460979 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sucking (NNS)
Number of subjects: 78
Study 24698195 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrostomy (PCN) tube
Number of subjects: 90
Study 24698195 — intervention group
Group type: EXPERIMENTAL
Intervention: JJ ureteric stenting
Number of subjects: 90
Study 23911345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass surgery
Number of subjects: 43
Study 23911345 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (diet and exercise)
Number of subjects: 43
Study 23911345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 43
Study 23911345 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the above
Number of subjects: 43
Study 23911345 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsure
Number of subjects: 43
Study 21653717 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic gradients applied to expanding dot patterns during fMRI scanning, with consistent depth cues (peripheral dots near, central dots far)
Number of subjects: 13
Study 21653717 — intervention group
Group type: COMPARATOR
Intervention: Stereoscopic gradients applied to expanding dot patterns during fMRI scanning, with inconsistent depth cues (central dots near, peripheral dots far)
Number of subjects: 13
Study 21653717 — intervention group
Group type: COMPARATOR
Intervention: Stereoscopic gradients applied to expanding dot patterns during fMRI scanning, with zero-disparity gradients
Number of subjects: 13
Study 21653717 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic gradients applied to expanding dot patterns during fMRI scanning
Number of subjects: 13
Study 19058059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal administration of 17beta-estradiol
Number of subjects: 270
Study 19058059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 17721962 — intervention group
Group type: EXPERIMENTAL
Intervention: Overshadowing the Threat of Terrorism program (8 sessions)
Number of subjects: 0
Study 17721962 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 15213488 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback group (n = 195)
Number of subjects: 282
Study 15213488 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention group (n = 87)
Number of subjects: 282
Study 11107086 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning
Number of subjects: 100
Study 11107086 — intervention group
Group type: COMPARATOR
Intervention: Computed tomographic (CT) angiography
Number of subjects: 100
Study 9490625 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies against IgE and IgD; tested using ELISA with peroxidase conjugated antibodies.
Number of subjects: 0
Study 9490625 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgG, IgM, and IgA antibodies with polysaccharide from Neisseria meningitidis serotype A; studied during vaccine testing.
Number of subjects: 0
Study 8195853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim (10 mg/kg on the first day, 5 mg/kg/day thereafter)
Number of subjects: 170
Study 8195853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 170
Study 8195853 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (560 mg/kg/8 hours)
Number of subjects: 170
Study 8195853 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (50 mg/kg/12 hours)
Number of subjects: 170
Study 8195853 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Erythromycin and Amoxicillin/clavulanic acid)
Number of subjects: 170
Study 3099313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 mcg) administered 25 min before a meal (anti-cibum AC)
Number of subjects: 30
Study 3099313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 mcg) administered 5 min after a meal (post-cibum PC)
Number of subjects: 30
Study 3099313 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 25 min before a meal (anti-cibum AC)
Number of subjects: 30
Study 3099313 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 5 min after a meal (post-cibum PC)
Number of subjects: 30
Study 3099313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (AC or PC)
Number of subjects: 30
Study 3099313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 30
Study 3099313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (PC)
Number of subjects: 30
Study 29752149 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb occlusion pressure (LOP) determination
Number of subjects: 93
Study 29752149 — intervention group
Group type: COMPARATOR
Intervention: Arterial occlusion pressure (AOP) estimation
Number of subjects: 93
Study 26881981 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium-feature hearing aids
Number of subjects: 45
Study 26881981 — intervention group
Group type: COMPARATOR
Intervention: Basic-feature hearing aids
Number of subjects: 45
Study 24433234 — intervention group
Group type: EXPERIMENTAL
Intervention: TIRSFSP guided by a stroke support person, delivered in-person during acute care and by telephone for approximately the first six to 12 months post-stroke
Number of subjects: 300
Study 24433234 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver self-directed TIRSFSP with an initial introduction to the program by a stroke support person
Number of subjects: 300
Study 24433234 — intervention group
Group type: COMPARATOR
Intervention: Standard care receiving the educational resource 'Let's Talk about Stroke' prepared by the Heart and Stroke Foundation
Number of subjects: 300
Study 22722516 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 201
Study 22722516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 19651631 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose PPI therapy
Number of subjects: 90
Study 19651631 — intervention group
Group type: COMPARATOR
Intervention: Low dose PPI therapy
Number of subjects: 90
Study 19651631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged PPI use
Number of subjects: 90
Study 19651631 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin (1 ng/ml) on OE33(E)(cckr) Barrett's oesophagus cells
Number of subjects: 90
Study 19651631 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin (100 ng/ml) on OE33(E)(cckr) Barrett's oesophagus cells
Number of subjects: 90
Study 18922570 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg)
Number of subjects: 2587
Study 18922570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2587
Study 15673861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 40 mug/kg IV
Number of subjects: 25
Study 15673861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 80 mug/kg IV
Number of subjects: 25
Study 15673861 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study 12085041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (NaP)
Number of subjects: 300
Study 12085041 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate (Mg)
Number of subjects: 300
Study 12085041 — intervention group
Group type: COMPARATOR
Intervention: Sodium Phosphate (NaP) diluted into 3 doses 10 minutes apart
Number of subjects: 300
Study 10435801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF)
Number of subjects: 0
Study 10435801 — intervention group
Group type: EXPERIMENTAL
Intervention: Late normal tissue damage
Number of subjects: 0
Study 7598849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 69
Study 7598849 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 69
Study 2195862 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion for 48 hours
Number of subjects: 103
Study 2195862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic glucose)
Number of subjects: 103
Study 368231 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose electrolyte solution
Number of subjects: 73
Study 368231 — intervention group
Group type: COMPARATOR
Intervention: Sucrose electrolyte solution
Number of subjects: 73
Study 368231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 73
Study 30221374 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar listeners
Number of subjects: 3
Study 30221374 — intervention group
Group type: COMPARATOR
Intervention: Familiar listeners
Number of subjects: 3
Study 29750828 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg once monthly for 12 months
Number of subjects: 7180
Study 29750828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7180
Study 29750828 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 7180
Study 23403530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with self-determined goal
Number of subjects: 41
Study 23403530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with specific goal of 2500 steps/day above baseline
Number of subjects: 41
Study 22385937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 0
Study 22385937 — intervention group
Group type: COMPARATOR
Intervention: Stepped pharmacologic care
Number of subjects: 0
Study 20516425 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/d
Number of subjects: 71
Study 20516425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 17706091 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy (VCO)
Number of subjects: 100
Study 17706091 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 100
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes
Number of subjects: 2115
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 2115
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height index
Number of subjects: 2115
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 2115
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cell function adjusted for insulin resistance
Number of subjects: 2115
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FPG > or =5.6 mmol/l, BMI > or =30 kg/m(2), and family history of diabetes
Number of subjects: 2115
Study 15616025 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG > or =6.1 mmol/l or 2-h glucose > or =7.8 mmol/l
Number of subjects: 2115
Study 11994796 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block using near-nerve electromyographically guided technique
Number of subjects: 41